ClinicalTrials.gg
RecruitingNCT07127874Updated Sep 29, 2026

A Study of PHN-012 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of PHN-012 in Colon Cancer, Pancreatic Cancer and Lung Cancer (NSCLC), sponsored by Pheon Therapeutics. Recruiting at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Pheon Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Sep 29, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
165
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Planned enrollment
227th of 864
165 · median 50
Started
2025
with 32 others
Phase 1
244 of 1,122
20 open now
Primary completion
2027-09
later than 107 of 187 live
Registered
1,084th of 1,122
by date

Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 227th largest by planned enrollment of the 864 interventional ones that give a count, is one of 33 that started in 2025, is one of 244 in phase 1, reaches primary completion later than 107 of the 187 other live ones, and was the 1,084th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,122 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

03

Conditions studied

  • Colon Cancer
  • Pancreatic Cancer
  • Lung Cancer (NSCLC)
  • Advanced Cancer
  • Advanced Solid Tumors

Keywords

  • Antibody Drug Conjugate
  • Carcinoma
  • Cancer
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed, advanced/:

    1. Colorectal adenocarcinoma (CRC), or
    2. Non-small cell lung cancer (NSCLC), or
    3. Pancreatic ductal adenocarcinoma (PDAC).
  • Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent , and for whom no further standard therapy is available or who is intolerant to standard therapy.
  • Has .
  • (ECOG) performance status of 0 or 1.
  • Has adequate organ function.
  • Has available tumor tissue sample at screening (either an or fresh biopsy material).

Exclusion criteria

Exclusion Criteria:

  • Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.
  • Has unstable central nervous system .
  • Has persistent toxicities from previous systemic anti-cancer treatments of Grade >1.
  • Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.
  • Has received wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.
  • Had major surgery (not including placement of vascular access device or tumor ) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.
  • Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic within 6 months prior to first dose of the study drug, active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Phase 1a and Phase 1b

    PHN-012 is administered intravenously

    Drug: PHN-012

Interventions

  • DrugPHN-012

    PHN-012 is an ADC

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (Phase 1a)

    Time frame: 12 months

  2. Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1a)

    Time frame: 12 months

  3. Frequency of dose interruptions, reductions, and discontinuations (Phase 1a and 1b)

    Time frame: 24 months

  4. Overall response rate (ORR) (Phase 1b)

    Time frame: 12 months

Secondary outcomes

  1. Best overall response (BOR) (Phase 1a and 1b)

    Time frame: 24 months

  2. Disease control rate (DCR) (Phase 1a and 1b)

    Time frame: 24 months

  3. Progression free survival (PFS) (Phase 1a and 1b)

    Time frame: 24 months

  4. Time to response (TTR) (Phase 1a and 1b)

    Time frame: 24 months

  5. Overall survival (OS) (Phase 1a and 1b)

    Time frame: 24 months

  6. Pharmacokinetics, maximum concentration (Cmax) of total ADC (Phase 1a and 1b)

    Time frame: 24 months

  7. Pharmacokinetics, Cmax of total antibody (Phase 1a and 1b)

    Time frame: 24 months

  8. Pharmacokinetics, Cmax of free payload (Phase 1a and 1b)

    Time frame: 24 months

  9. Pharmacokinetics, time of Cmax (Tmax) of total ADC (Phase 1a and 1b)

    Time frame: 24 months

  10. Pharmacokinetics, Tmax of total antibody (Phase 1a and 1b)

    Time frame: 24 months

  11. Pharmacokinetics, Tmax of free payload (Phase 1a and 1b)

    Time frame: 24 months

  12. Pharmacokinetics, area under the curve (AUC) of total ADC (Phase 1a and 1b)

    Time frame: 24 months

  13. Pharmacokinetics, AUC of total antibody (Phase 1a and 1b)

    Time frame: 24 months

  14. Pharmacokinetics, AUC of total free payload (Phase 1a and 1b)

    Time frame: 24 months

  15. Pharmacokinetics, terminal half-life (t1/2) of total ADC (Phase 1a and 1b)

    Time frame: 24 months

  16. Pharmacokinetics, t1/2 of total antibody (Phase 1a and 1b)

    Time frame: 24 months

  17. Pharmacokinetics, t1/2 of free payload (Phase 1a and 1b)

    Time frame: 24 months

  18. Concentration of anti-drug antibodies (Phase 1a and 1b)

    Time frame: 24 months

  19. Type, incidence and severity of AEs and SAEs (Phase 1b)

    Time frame: 12 months

07

Study locations

26 of 26 sites recruiting
  • PHN-012-001 Site
    Los Angeles, California 90033, United States
    Recruiting
  • PHN-012-001 Site
    San Diego, California 92037, United States
    Recruiting
  • PHN-012-001 Site
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • PHN-012-001 Site
    Boston, Massachusetts 02114, United States
    Recruiting
  • PHN-012-001 Site
    St Louis, Missouri 63108, United States
    Recruiting
  • PHN-012-001 Site
    Durham, North Carolina 27710, United States
    Recruiting
  • PHN-012-001 Site
    Portland, Oregon 97239, United States
    Recruiting
  • PHN-012-001 Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • PHN-012-001 Site
    Houston, Texas 77030, United States
    Recruiting
  • PHN-012-001 Site
    San Antonio, Texas 78229, United States
    Recruiting
  • PHN-012-001 Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • PHN-012-001 Site
    Seoul, Gangnam-gu 06351, South Korea
    Recruiting
  • PHN-012-001 Site
    Seongnam-si, Gyeonggi-do 13496, South Korea
    Recruiting
  • PHN-012-001 Site
    Seoul, Jongno-gu 03080, South Korea
    Recruiting
  • PHN-012-001 Site
    Seoul, Seodaemun-gu 03722, South Korea
    Recruiting
  • PHN-012-001 Site
    Seoul, Seoucho-gu 06591, South Korea
    Recruiting
  • PHN-012-001 Site
    Seoul, Songpa-gu 05505, South Korea
    Recruiting
  • PHN-012-001 Site
    Barcelona, Community of Catalonia 08023, Spain
    Recruiting
  • PHN-012-001 Site
    Barcelona, Community of Catalonia 08035, Spain
    Recruiting
  • PHN-012-001 Site
    Madrid, Madrid 28007, Spain
    Recruiting
  • PHN-012-001 Site
    Madrid, Madrid 28027, Spain
    Recruiting
  • PHN-012-001 Site
    Madrid, Madrid 28034, Spain
    Recruiting
  • PHN-012-001 Site
    Madrid, Madrid 28040, Spain
    Recruiting
  • PHN-012-001 Site
    Madrid, Madrid 28050, Spain
    Recruiting
  • PHN-012-001 Site
    Valencia, Valencia 46009, Spain
    Recruiting
  • PHN-012-001 Site
    Valencia, Valencia 46010, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 116 studies reached it within 48 months; a quarter within 32 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Sep 2027
CompletionEst.
May 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
  • PHN-012-001 Site · Seongnam-si, South KoreaNot yet recruiting→Recruiting
  • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
  • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
  • PHN-012-001 Site · Madrid, SpainNot yet recruiting→Recruiting
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
    • PHN-012-001 Site · Seongnam-si, South KoreaNot yet recruiting→Recruiting
    • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
    • PHN-012-001 Site · Seoul, South KoreaNot yet recruiting→Recruiting
    • PHN-012-001 Site · Madrid, SpainNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07127874
Lead sponsor
Pheon Therapeutics
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Sep 23, 2025
Primary completion
Sep 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Myles Clancy
Contact
PHN012001trial@pheontx.com
1-857-342-3090

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion